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Abstract 6-Phosphofructo-2-kinase catalyzes the synthesis and
degradation of fructose 2,6-bisphosphate, activator of phospho-
fructokinase-1 and inhibitor of fructose 1,6-bisphosphatase.
These properties confer to this bifunctional enzyme a key role
in the control of glycolysis and gluconeogenesis. Several mam-
malian isozymes generated by alternative splicing from four
genes, designated pfkfb1^4, have been identi¢ed. The results
presented in this study demonstrate the expression of the pfkfb3
gene in C2C12 cells and its downregulation during myogenic
cell di¡erentiation. We also show that the decrease of ubiquitous
6-phosphofructo-2-kinase isozyme levels, product of pfkfb3
gene, is due to its enhanced degradation through the ubiquitin-
proteasome proteolytic pathway.
+ 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Skeletal muscle di¡erentiation is characterized by terminal
withdrawal from the cell cycle, the coordinated activation of
muscle-speci¢c gene expression, and the fusion of myoblasts
into multinucleated myotubes [1^3]. All these events are coor-
dinated by a family of muscle-speci¢c basic helix-loop-helix
(bHLH) transcription factors, belonging to the MyoD family,
that include MyoD [4], Myf5 [5], myogenin [6] and MRF4 [7].
Members of the MyoD family heterodimerize with ubiqui-
tously expressed members of the E-protein family and bind
to a DNA consensus CANNTG, known as an E-box, found
in promoters of several muscle-speci¢c genes [8,9].
6-Phosphofructo-2-kinase [EC 2.7.1.105]/fructose 2,6-bis-
phosphatase [EC 3.1.3.46] (PFK-2) is a homodimeric bifunc-
tional enzyme that catalyzes the synthesis and degradation of
fructose 2,6-bisphosphate (Fru-2,6-P2) [10]. Fru-2,6-P2 is the
most powerful activator of phosphofructokinase-1 and an in-
hibitor of fructose 1,6-bisphosphatase [10^13]. These proper-
ties confer to this bifunctional enzyme a key role in the con-
trol of glycolysis and gluconeogenesis. Since the discovery of
this system in liver, other mammalian tissue-speci¢c bifunc-
tional isozymes have been identi¢ed. These isozymes are gen-
erated by alternative splicing from four genes, designated
pfkfb1^4 [10], and they di¡er in physicochemical, immunolog-
ical and functional properties, as well as in their response to
phosphorylation by protein kinases. The expression of pfkfb
genes is regulated by hormones, growth factors and metabo-
lites, that control tissue-speci¢c isoforms. Pfkfb3 gene ac-
counts for two reported isoforms, ubiquitous (uPFK-2) and
inducible, generated through the alternative splicing of exon
15 [14]. Pfkfb3 gene product has the highest kinase:phospha-
tase activity ratio and thus maintains elevated Fru-2,6-P2 lev-
els, which in turn sustains high glycolytic rates in the cell [15^
17]. This gene has been related to proliferation because it is
ubiquitously expressed in di¡erent tissues and in transformed
cell lines and tumors [16^19] and transfection of antisense
oligonucleotides against this gene in K562 leukemia cells pro-
duces an inhibition of DNA synthesis and cell proliferation
[18]. Furthermore, it has been recently found that it is highly
induced by hypoxia through the hypoxia-inducible transcrip-
tion factor-1 complex [20] and modulated by adenosine mono-
phosphate (AMP)-kinase-dependent phosphorylation [21].
The aim of this report is to study pfkfb3 gene expression
and regulation during muscle di¡erentiation of C2C12 cells.
Our results show that during myogenesis, the expression of
pfkfb3 decreases and the uPFK-2 gene product is degraded
through the ubiquitin-proteasome proteolytic pathway.
2. Materials and methods
2.1. Plasmid constructs
Pfkfb3 cDNA encoding the human uPFK-2 was cloned into
pcDNA3.1 vector for cellular expression (uPFK-pc3) as described
previously [16]. The expression vector pMT107 contains a ubiquitin
His-tagged cDNA obtained as described [22]. The glutathione S-trans-
ferase (GST)-ubiquitin is a bacterial expression vector for the ubiq-
uitin cDNA fused to the GST protein, and it was generated and
described elsewhere [22].
2.2. Cell culture and transfection
All cell lines are cultured at 37‡C with 95% humidity and 10% CO2.
C2C12 cells were cultured in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) supplemented with 20% fetal bovine serum (FBS). Muscle
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di¡erentiation was induced by culturing subcon£uent C2C12 cells in
DMEM supplemented with 2% FBS. HEK-293T cells were cultured in
DMEM supplemented with 10% FBS and 1 mM sodium pyruvate.
C2C12 and HEK-293T cells were transiently transfected with the in-
dicated vectors using the calcium phosphate transfection method as
described [23]. N-acetyl-leucinyl-leucinyl-N-norleucinal (LLnL) (Sig-
ma) (50 WM) was added 8 h before cell harvesting. Des(1,2,3)insu-
lin-like growth factor (IGF)-I was from Dra Angelika F. Schutzdeller
(Tubingen, Germany) and bone morphogenic protein (BMP)-2 from
Genetics Institute (Cambridge, MA, USA).
2.3. RNA analysis by Northern blot hybridization and reverse
transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from cultured C2C12 cells (1U107 cells)
using an RNA isolation kit following the manufacturer’s protocol
(Ultraspec RNA Biotecx Laboratories). A partial cDNA clone of
0.7 kb, corresponding to the 3P-untranslated region (UTR) of mouse
uPFK-2 (accession number AF294617), was used as a probe. The
probe was directly labeled by incorporation of [32P]K-dCTP using
standard procedures. RNA was separated by electrophoresis on a
1% agarose-formaldehyde gel and transferred to nylon membranes
using capillary transfer. Hybridization was carried out at 42‡C, and
membranes were then washed three times at 46‡C in 0.1% sodium
dodecyl sulfate (SDS) and 0.1Ustandard saline citrate (SSC) and sub-
jected to autoradiography by exposing to Kodak MS ¢lm for 36 h at
380‡C. mRNA levels were normalized using ribosomal RNA £uores-
cent intensity in the agarose-formaldehyde gel.
For RT-PCR conditions: 1 Wg of total RNA was reverse-tran-
scribed using a Ready-To-Go T-Primed First-Strand Kit from Phar-
macia Biotech (Uppsala, Sweden). PCR ampli¢cation was carried out
using reverse-transcribed RNA and forward primer Mus 1 and reverse
primer Mus 3 (5P-GGGCGCTTCCTCAGCCT-3P and 5P-ATCCTT-
TAGGGCTGCTAGAG-3P, respectively) for uPFK-2, myog1 and
myog2 (5P-AGTGAATGCAACTCCCACAGCGCCT-3P and 5P-TG-
GCTTGTGGCAGCCCAGGG-3P) for myogenin, and gapdh1 and
gapdh2 (5P-CAAAGTGGACATTGTTGCCATC-3P and 5P-GCGC-
AGTAGACTCCACGACA-3P) for glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH).
2.4. Western blot analysis
Total cellular protein was obtained from C2C12 cells using 500 Wl
of extraction bu¡er (0.5 M Tris^HCl at pH 6.8 with 1% SDS) for
5 min at 95‡C. 50 Wg of total cellular protein were separated on 8%
SDS^polyacrylamide gel under reducing conditions and then trans-
ferred to polyvinylidene di£uoride (PVDF) membrane (Millipore,
Bedford, MA, USA). The membrane was probed with a speci¢c anti-
body against the C-terminus of uPFK2 [17], inducible PFK-2 (Santa
Cruz), liver PFK-2 (Santa Cruz), anti-myogenin antibody F5D (Phar-
mingen), anti-L-actin (Sigma) or anti-K-tubulin (Calbiochem). Immu-
noreactive proteins were then visualized by developing membranes
with a horseradish peroxidase-conjugated anti-rabbit or anti-mouse
IgG antibody (1:5000) followed by incubation with electrochemolu-
minescent (ECL) Western blot reagent (Amersham Pharmacia Bio-
tech, Uppsala, Sweden).
2.5. Fru-2,6-P2, lactate and creatine kinase assays
Fru-2,6-P2 was measured by a modi¢cation of the method described
by Van Schaftingen et al. [24]. Extracts were obtained by washing the
cells twice in ice-cold phosphate-bu¡ered saline (PBS) and then scrap-
ing the cell layer in 0.4 ml of 100 mM NaOH with 0.1% Triton X-100
and centrifuged at 10 000 rpm for 10 min at 4‡C. Creatine kinase
activity was measured in C2C12 extracts obtained by washing the
cells twice in ice-cold PBS and then scraping the cell layer in 0.4 ml
of PBS with 0.1% Triton X-100 and centrifuged at 10 000 rpm for
10 min at 4‡C. Supernatants were incubated for 5 min at 30‡C with
1 ml of the reaction mix (23 mM cysteine, 2.3 mM adenosine diphos-
phate (ADP), 23 mM D-glucose, 2.3 mM nicotinamide adenine dinu-
cleotide phosphate (NADP), 4000 U/l hexokinase, 2300 U/l glucose
6-phosphate dehydrogenase) in reaction bu¡er (128 mM imidazole,
2.5 mM ethylenediamine tetraacetic acid (EDTA), 12.8 mM magne-
sium acetate at pH 6.7). The reaction was initiated with creatine
phosphate, detecting the change in absorbance at 340 nm. One crea-
tine kinase unit corresponds to the amount of enzyme that catalyzes
the synthesis of 1 Wmol of product per min. Lactate was measured by
mixing 1 ml of culture medium with 1 ml of 10% HClO4. After 10 min
at 0‡C and centrifugation at 2000Ug for 10 min, the supernatant was
neutralized with 3 M KOH-KHCO3 and lactate concentration mea-
sured as described [25].
2.6. Protein stability
uPFK-2 was labeled with [35S]methionine in an in vitro transcrip-
tion/translation reaction using the manufacturer’s protocol (Promega).
C2C12 cells at 0 or 3 days after initiation of muscle di¡erentiation
were trypsinized and cell pellets were obtained by centrifugation at
1000 rpm for 5 min at 4‡C. Cell pellets were washed twice with ice-
cold PBS and resuspended in 100 ml of 10 mM Tris, pH 8.0 for 10 min
and sonicated brie£y. Cell debris was removed by centrifugation at
10 000 rpm for 10 min at 4‡C. The protein concentration of the re-
sultant supernatant was determined by bicinchoninic acid (BCA) pro-
tein assay (Pierce). For the stability assay, 150 Wg of total protein was
mixed with 10 Wl of 35S-labeled uPFK-2, and the volume adjusted to
130 Wl using lysis bu¡er. Following incubation at 30‡C for various
periods of time, 40 Wl of the reaction mixture was taken and the
reaction stopped by adding 2USDS sample bu¡er. Samples were
boiled for 3 min and separated on a 8% SDS^polyacrylamide gel
electrophoresis (PAGE). Following migration, the gel was ¢xed in
20% methanol, 10% acetic acid for 30 min, dried and exposed to
Kodak XR ¢lm at 380‡C. If treatment with LLnL (Sigma) was re-
quired, C2C12 cells were di¡erentiated in DMEM with 2% FBS and
8 h before cell collection were treated with 50 WM of the proteasome
inhibitor LLnL dissolved in dimethyl sulfoxide (DMSO) or with the
same volume of DMSO in fresh medium. Following treatment, cells
were harvested and uPFK-2 levels quanti¢ed by Western blot as de-
scribed above.
For in vivo stability C2C12 cells di¡erentiated for 3 days in 2% FBS
or in growing medium (20% FBS) were incubated for 0, 1, 2, 4 or 8 h
in the presence of 10 Wg/ml of the protein synthesis inhibitor cyclo-
heximide. After these times, cells were lysed and uPFK-2 levels quan-
ti¢ed by Western blot as described above.
2.7. Ubiquitin binding assays
To detect ubiquitinated uPFK-2 in vivo, subcon£uent cultures of
HEK-293T cells were transfected as described above with 2 Wg of
empty vector or uPFK-pc3 expression constructs, in either the pres-
ence or absence of 4 Wg of the plasmid pMT107, which encodes His-
tagged human ubiquitin. After 20^24 h, cells were treated with 50 WM
of the proteasome inhibitor LLnL dissolved in DMSO or with the
same volume of DMSO in fresh medium for 8 h. Cell extracts were
prepared after washing cells twice in cold PBS by boiling cells for
5 min with 50 mM Tris^HCl, 1% SDS at pH 6.8. Protein concentra-
tion was determined using a BCA protein assay (Pierce). Samples were
diluted in eight volumes of pull-down bu¡er (50 mM Tris^HCl,
150 mM NaCl, 0.2% NP-40, 10% glycerol, 20 mM imidazole at pH
7.4) with protease and phosphatase inhibitors as described [22]. His-
tidine-tagged proteins were puri¢ed on nickel-nitrilotriacetic acid
(NTA)-agarose (Qiagen) and uPFK-2 was detected by SDS^PAGE
and immunoblotting as described above.
For in vitro uPFK-2 ubiquitination, in vitro translated 35S-labeled
human uPFK-2 (25 Wl) was incubated with 5 Wg of GST or GST-
ubiquitin at 30‡C for 1 h. GST proteins were puri¢ed on glutathione-
Sepharose (Amersham-Pharmacia) and analyzed by SDS^PAGE.
After electrophoresis, gels were stained with Coomassie blue, dried
and autoradiographed (Kodak XR ¢lm) at 380‡C.
3. Results
3.1. Pfkfb3 gene expression during myogenic di¡erentiation of
C2C12 cells
As previously described, C2C12 cells with a limited supply
of growth factors di¡erentiate into myoblasts, that later fuse
into multinucleated myotubes [1^3]. To promote di¡erentia-
tion, subcon£uent C2C12 cells were serum-starved for up to
7 days. On microscopic examination of the cultures we ob-
served the expected morphological changes, namely cell align-
ment and fusion into multinucleated myotubes (data not
shown). Total RNA was extracted from C2C12 cells at di¡er-
ent days of di¡erentiation to determine the expression of
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uPFK-2 mRNA by Northern blot (Fig. 1A). Myogenic di¡er-
entiation of the C2C12 cells produced a progressive decrease
of uPFK-2 mRNA levels, showing that pfkfb3 gene expres-
sion was downregulated during this process. These results
were con¢rmed using RT-PCR analysis (Fig. 1B).
3.2. Fru-2,6-P2 and uPFK-2 expression during myogenic
di¡erentiation
To examine the e¡ect of myogenic di¡erentiation on the
levels of uPFK-2 protein, we performed Western blot analysis
of C2C12 protein extracts at di¡erent days of di¡erentiation
with a speci¢c antibody against the C-terminus of the ubiq-
uitous isozyme that does not recognize the inducible isoform
[17] (Fig. 2A). uPFK-2 expression decreased throughout the
di¡erentiation process, being barely detectable after 3 days,
whereas myogenin, a marker of di¡erentiation, showed a tran-
sient increase in expression with a peak at 2 days. Inducible or
liver PFK-2, products of the pfkfb3 and pfkfb1 gene, respec-
tively, were not detectable during this process (data not
shown). Correlating with uPFK-2 levels, the concentration
of Fru-2,6-P2 decreased and a lower lactate was observed in
3 days extracts (62.9 V 4.2 Wmol lactate/mg protein in 2% FBS
cells versus 80.6V 9.3 Wmol lactate/mg protein in 20% FBS
Fig. 1. Pfkfb3 gene expression during muscle di¡erentiation of
C2C12 cells. A: Total RNA was extracted from C2C12 cells at dif-
ferent days of myogenic di¡erentiation and analyzed by Northern
blot with a speci¢c probe for mouse ubiquitous pfkfb3 as described
in Section 2. Lower panel shows the levels of RNA loaded in each
lane stained with ethidium bromide. B: For RT-PCR analysis, total
RNA was reverse-transcribed using a Ready-To-Go T-Primed First-
Strand Kit from Pharmacia Biotech (Uppsala, Sweden). PCR ampli-
¢cation was carried out using reverse-transcribed RNA with speci¢c
primers, as described in Section 2.
Fig. 2. PFK-2 protein level and Fru-2,6-P2 concentration. A: 100 Wg
of whole protein extract from C2C12 cells at di¡erent times of myo-
genic di¡erentiation were resolved by SDS^PAGE and analyzed by
Western blot with anti-uPFK-2, with anti-myogenin and with anti-
K-tubulin as described in Section 2. B: Determination of the con-
centration of Fru-2,6-P2 (pmol/mg of protein, 8) and creatine ki-
nase activity (mU/mg of protein, R). Each point represents the
meanVS.E.M. of three independent experiments. C: Western blot
against uPFK-2 from NIH3T3 whole extracts incubated for di¡erent
times with 2% of serum and normalized with L-actin. D: C2C12
cells treated with 2 nM desIGF-I or 2 nM BMP-2 at 2% FBS. Rep-
resentative experiments are shown.
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cells) whereas creatine kinase activity increased during myo-
genic di¡erentiation (Fig. 2B). To con¢rm the speci¢c impli-
cation of muscle di¡erentiation and rule out the possible e¡ect
on uPFK-2 expression of reduced serum during di¡erentia-
tion, we cultured NIH3T3 cells with 2% of serum in the me-
dium and analyzed the amount of uPFK-2 protein by Western
blot at di¡erent times during di¡erentiation. As shown in Fig.
2C, after 3 days of serum starvation we did not detect varia-
tions in the uPFK-2 protein level. These results indicate that
downregulation in uPFK-2 expression is dependent on the
myogenic process.
Furthermore, we induced C2C12 di¡erentiation in low se-
rum concentration using desIGF-I, a known myogenic di¡er-
entiation factor which increases myogenesis and myogenin in
this cell model [26]. The results obtained show a 85% decrease
in uPFK-2 protein levels during the ¢rst 24 h while the same
percentage of reduction using the serum starvation protocol
was observed after 3 days (Fig. 2D). In addition, we also
found a decrease in the expression of uPFK-2 in C2C12 cells
in the presence of BMP-2 (Fig. 2D). The presence of BMP-2
in C2C12 cells cultured with 2% FBS stops the di¡erentiation
process into myotubes and promotes the di¡erentiation into
osteoblasts [27]. Taken together these results suggest that the
decrease in uPFK-2 levels is dependent on cell di¡erentiation.
3.3. Protein stability of uPFK-2 during myogenic di¡erentiation
To investigate the stability of uPFK-2 during myogenic
di¡erentiation, we labeled uPFK-2 using an in vitro transcrip-
tion and translation method (see Section 2) and incubated it
with C2C12 cell extracts from 0 or 3 days of di¡erentiation
and the amount of uPFK-2 was analyzed (Fig. 3A). The re-
sults obtained showed a faster disappearance of the ubiqui-
tous protein when incubated with the C2C12 extracts from
3 days of di¡erentiation (Fig. 3B) as compared to the levels
obtained when the protein was incubated with extracts from
Fig. 3. In vitro degradation of uPFK-2 during myogenic di¡erentia-
tion. A: 10 Wl of in vitro translated 35S-labeled uPFK-2 was incuba-
ted in the presence of 150 Wg of total protein extracts from C2C12
cells at 0 or 3 days of myogenic di¡erentiation for the indicated pe-
riods of time at 30‡C. Following electrophoresis, [35S]uPFK-2 was
visualized by autoradiography. Asterisk shows the bands of high
molecular weight that appeared in the 3 days extracts. B: Densito-
metric quanti¢cation of the remaining protein with respect to the
protein present at 0 h represented as 100%, each point represents
the meanVS.E.M. of three independent experiments. C: C2C12 cells
at 0 (a) or 3 days (b) of myogenic di¡erentiation were incubated
for the periods of time indicated in the presence of 10 Wg/ml of the
protein synthesis inhibitor cycloheximide. Cells were lysed and
uPFK-2 was immunodetected by Western blot. Results were quanti-
¢ed by densitometric analysis. Results are the mean of two indepen-
dent experiments.
Fig. 4. The proteasome pathway is involved in the regulation of
uPFK-2. Whole extracts from C2C12 at di¡erent days of di¡erentia-
tion, incubated with (+) or without (3) 50 WM of LLnL for 8 h,
were analyzed by Western blot against uPFK-2. Anti-ubiquitin im-
munodetection was made as a control of the action of the protea-
some inhibitor and the immunoblot with anti-tubulin protein as
load control. A representative experiment is shown.
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cells before di¡erentiation. Moreover, uPFK-2 in these ex-
tracts was processed and appeared as higher molecular weight
bands (* in Fig. 3A), suggesting a post-translational modi¢-
cation of the protein. A post-translational modi¢cation that
could produce this characteristic shift of the molecular weight
is protein ubiquitination and this modi¢cation is related to
protein degradation by the proteasome complex. We also de-
termined uPFK-2 half-live in C2C12 either exponentially,
growing in high serum media, or after 3 days of myogenic
di¡erentiation, induced by serum deprivation. Results shown
in Fig. 3C indicate that myogenic di¡erentiation decreased
uPFK-2 half-life almost to 50% of that of exponentially grow-
ing cells, further suggesting an increased degradation in di¡er-
entiating C2C12 cells.
3.4. Implication of the ubiquitin-proteasome proteolytic
pathway in the degradation of uPFK-2
Due to the importance of the ubiquitin-proteasome proteo-
lytic pathway during muscle di¡erentiation [28], we studied
the implication of this pathway in the speci¢c degradation
of uPFK-2 protein. C2C12 cells were cultured for 0^3 days
in di¡erentiation media and 8 h before harvesting 50 WM
LLnL, a proteasome inhibitor, was added and the levels of
uPFK-2 analyzed in cell extracts by Western blot analysis. As
shown in Fig. 4, uPFK-2 protein decreased in control cells
whereas cells treated with the proteasome inhibitor main-
tained uPFK-2 protein levels. These results demonstrate the
involvement of ubiquitin-proteasome proteolytic pathway in
the decrease of uPFK-2 during myogenic di¡erentiation.
In order to determine whether uPFK-2 could be ubiquiti-
nated in vitro, we performed pull-down experiments with glu-
tathione beads incubated with [35S]methionine radiolabeled
uPFK-2 protein, synthesized using a rabbit reticulocyte sys-
tem, and GST or GST-ubiquitin. Pull-down pellets were re-
solved by SDS^PAGE and the ubiquitous isozyme detected by
autoradiography (Fig. 5A). uPFK-2 incubated with GST-
ubiquitin was resolved in multiple bands of high molecular
weight after the pull-down due to the ubiquitination of
uPFK-2 in the reticulocyte extracts, whereas uPFK-2 incuba-
ted with GST alone was not ubiquitinated. The bands of high-
er molecular weight corresponding to uPFK-2 are consistent
with the covalent cross-linking of multiple GST-ubiquitin
moieties (35 kDa) to uPFK-2 protein. After pull-down we
could observe monoubiquitinated as well as several polyubi-
quitinated forms of uPFK-2. The ubiquitination of uPFK-2
might target the protein to proteasome-mediated degradation.
To con¢rm this hypothesis, we tested the e¡ect of the protea-
some inhibitor LLnL on uPFK-2 levels in vivo. As shown in
Fig. 5B, treatment of HEK-293T cells with LLnL resulted in
an increase of uPFK-2 levels and accumulation of ubiquiti-
nated uPFK-2 in pull-down extracts. In conditions where
uPFK-2 cDNA and ubiquitin His6-tag were overexpressed,
we could only detect uPFK-2 after the pull-down Ni bead
extracts when cells were coexpressing both constructs. In these
conditions we detected higher molecular weight bands show-
ing that uPFK-2 is ubiquitinated in vivo.
4. Discussion
A remarkable property of cultured C2C12 cells is the acti-
vation of the myogenic program upon changes of culture con-
ditions (serum withdrawal), characterized by a cell cycle exit
Fig. 5. Ubiquitination of uPFK-2. A: In vitro ubiquitination assay.
Radiolabeled uPFK-2 by in vitro translation was incubated with ei-
ther GST or GST-ubiquitin (GST-ub). After pull-down with gluta-
thione beads, protein were eluted from the beads with sample bu¡er
containing dithiothreitol (DTT) and resolved by SDS^PAGE in par-
allel with rabbit reticulocyte lysate containing the incubation mix
before the pull-down (lysate lanes). uPFK-2 was detected by autora-
diography of the gel. B: In vivo ubiquitination of uPFK-2. HEK-
293T cells were transiently transfected with pcDNA3 vector alone
(lanes 1 and 2), with uPFK-pc3 (lanes 5^8) or with pMT107 (lanes
3, 4, 7 and 8), in the presence (+) or absence (3) of 50 WM of
LLnL. The amount of protein of each transfection was normalized
before the pull-down with Ni beads. Proteins were eluted from
beads with sample bu¡er and electrophoresed by SDS^PAGE.
uPFK-2 present in the pull-down samples was detected by immuno-
blot with a speci¢c antibody. The middle and lower panels show the
overexpression of ubiquitin and uPFK-2 in the normalized extracts
before the pull-down by immunoblotting with anti-his6 for ubiquitin
or with anti-uPFK-2 for uPFK-2. Both panels are representative of
two independent experiments.
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and muscle di¡erentiation [1^3]. Since the isolation of the
pfkfb3 gene from brain [16,29], placenta [30] and several cell
lines [17,18,31], this gene has been characterized by its ubiq-
uitous distribution and its presence in proliferating and trans-
formed cell lines, as well as in tumors [16^19]. The high ki-
nase/bisphosphatase activity of this gene product can explain
the high Fru-2,6-P2 concentration found in the cells where it is
present, which in turn sustains high glycolytic rates [15]. There
is evidence of an upregulation of its expression in response to
di¡erent stimuli such as progesterone [31], serum, insulin [17],
proin£ammatory molecules [18] or hypoxia [20]. The results
presented in this study demonstrate that pfkfb3 gene is ex-
pressed in C2C12 cells and it is downregulated during myo-
genic cell di¡erentiation, correlating with a decrease in the
amount of the enzyme. We also demonstrate that the de-
creases in uPFK-2 protein levels are due to its enhanced deg-
radation through the ubiquitin-proteasome proteolytic path-
way.
In adult muscle, a muscle-speci¢c PFK-2 isozyme derived
from pfkfb1 gene is present. Vandoolaeghe et al. [32] inves-
tigated at what stage of di¡erentiation the pfkfb1 muscle-spe-
ci¢c (M) promoter became functional, showing that muscle
PFK-2 did not appear during di¡erentiation of L6 myoblasts
into myotubes induced by growth factor withdrawal and hor-
monal treatment, and demonstrating that this isozyme is a
marker of mature skeletal muscle. There is no evidence for
the presence of pfkfb1 gene products (liver or muscle iso-
zymes) or inducible PFK-2 in di¡erentiated C2C12 cells. In
contrast, the expression of pfkfb3 decreases and the uPFK-2
protein gene product is degraded during myogenesis.
In order to con¢rm that this decline in pfkfb3 gene expres-
sion and uPFK-2 protein levels are due to di¡erentiation and
not to serum starvation, we determined the levels of uPFK-2
on NIH3T3 ¢broblast cells that do not di¡erentiate when
cultured in 2% FBS medium. As observed in Fig. 2C, the
levels of uPFK-2 protein were kept constant during the
3 days of culture. In addition, we accelerated di¡erentiation
of C2C12 in 2% FBS medium using desIGF (a myogenic
di¡erentiation factor) [26], observing a more pronounced de-
crease in uPFK-2 protein levels 24 h after addition of the
di¡erentiation factor (Fig. 2D). Altogether, these observations
con¢rmed the hypothesis that myogenic di¡erentiation in
C2C12 cells parallels a decrease in pfkfb3 gene expression.
However, BMP-2 which promotes transdi¡erentiation from
the myogenic to the osteogenic lineage [27] also induced a
pronounced decrease in uPFK-2 protein levels. This fact sug-
gests that likely the decreases in uPFK-2 levels are more re-
lated to the exit from the cell cycle than to the commitment to
a speci¢c cell fate.
In the past few years, there has been an increasing interest
for the ubiquitin-proteasome pathway of protein degradation
[33]. This proteolytic pathway is essential for the myogenic
di¡erentiation and inhibitors of the proteasome, such as lac-
tacystin, reversibly block both the fusion of L6 myoblasts and
the accumulation of muscle-speci¢c proteins [28,34] ; more-
over, the subunit composition of proteasomes changes when
the dividing C2C12 myoblasts fuse into myotubes [35] and
this proteolytic pathway is also implicated in the degradation
of MyoD during the G1 phase of the cell cycle [36]. The
results presented in the current study are the ¢rst direct dem-
onstration of the implication of the ubiquitin-proteasome pro-
teolytic pathway in the degradation of uPFK-2. In vivo, the
ubiquitous isozyme has a half-life of 6 h at the third day of
di¡erentiation as compared to more than 10 h in undi¡eren-
tiated cells (Fig. 3B). These di¡erences in the half-life of
uPFK-2 can be explained by the enhanced degradation of
this isozyme during myogenesis.
Amino acid sequence analysis reveals that uPFK-2 contains
one putative PEST sequence in its C-terminal, sequences that
are common to many short-lived proteins and reported to be
motifs for rapid degradation [37]. Furthermore, uPFK-2 also
contains a DSG8XS motif that is present in many proteins,
such as UB, L-catenin or Vpu, and whose phosphorylation on
the two serines is required for ubiquitin-dependent degrada-
tion [38]. Although the presence of these motifs in the uPFK-2
sequence, their relative relevance in uPFK-2 degradation
needs further investigation.
The expression and activity of the pfkfb3 gene are highly
regulated during proliferation and di¡erentiation processes at
multiple levels. This gene can be regulated by di¡erent growth
factors or hypoxia [17^20] and herein we show an additional
control via its degradation by the ubiquitin-proteasome pro-
teolytic pathway. In conclusion, pfkfb3 gene seems to play an
important role sustaining the high glycolytic £ux of prolifer-
ating cells, while its expression is downregulated and the cor-
responding protein degraded through the ubiquitin-protea-
some proteolytic pathway during C2C12 cell di¡erentiation.
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